Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation-Reference-Cited by-同舟云学术

Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation

Published:2018-10-18 Issue:4 Volume:54 Page:601-606
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Shah Mithun Vinod,Saliba Rima M.,Rondon Gabriela,Chen Julianne,Soebbing Doris,Rus Ioana,Alousi Amin,Oran Betul,Kebriaei Partow,Qazilbash Muzaffar^ORCID,Parmar Simrit,Hosing Chitra,Khouri Issa F.,Popat Uday R.,Champlin Richard E.,Ciurea Stefan O.

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/s41409-018-0367-2.pdf

Reference26 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA. 2017;67:7–30. https://doi.org/10.3322/caac.21387

2. Yq Sun, Lp Xu, Xh Zhang, Dh Liu, Chen H, Wang Y, et al. A retrospective comparison of BU-fludarabine and BU-CY regimens in elderly patients or in patients with comorbidities who received unmanipulated haploidentical hematopoietic SCT. Bone Marrow Transplant. 2015;50:601–3. https://doi.org/10.1038/bmt.2014.303

3. Ciurea SO, Rodrigues M, Giralt S, de Lima M. Aging, acute myelogenous leukemia, and allogeneic transplantation: do they belong in the same sentence? Clin Lymphoma Myeloma. 2009;9:289–97. https://doi.org/10.3816/CLM.2009.n.057

4. Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant. 2007;13:454–62. https://doi.org/10.1016/j.bbmt.2006.11.024

5. Popat U, de Lima MJ, Saliba RM, Anderlini P, Andersson BS, Alousi AM, et al. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. Bone Marrow Transplant. 2012;47:212–6. https://doi.org/10.1038/bmt.2011.61

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Graft Versus Host Disease Prophylaxis in Matched Donor Stem Cell Transplantation: Post-transplantation Cyclophosphamide Combinations Versus Methotrexate/Tacrolimus;Transplantation Proceedings;2024-09

3. Posttransplant cyclophosphamide versus anti‐thymocyte globulin versus combination for graft‐versus‐host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party;Cancer;2024-05-17

4. Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification;Blood Reviews;2023-11

5. Chronic graft-versus-host disease in pediatric patients: Differences and challenges;Blood Reviews;2023-07